文献速递技术与安全腹部US

超声造影剂成像:现状与未来

Imaging with ultrasound contrast agents: current status and future.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

本文综述了微泡超声造影剂(UCAs)的物理原理、给药方法、剂量、不良反应及当前与未来的成像技术。UCAs 经美国食品药品监督管理局批准用于非心脏成像,具有安全性记录良好、无肾毒性、可实时便携成像等优势,适用于 CT 和 MR 增强禁忌或不切实际时的腹部横断面成像。

要点

  • UCAs 经静脉给药后局限于血池,不同于碘剂和钆剂。
  • UCAs 不良反应较 CT/MR 造影剂少见,且无肾毒性,可用于肾功能衰竭。
  • 机械指数 < 0.4 的成像可保留微泡,通常不伴显著生物效应。

核心结论

  • 超声造影剂是诊断成像工具包中的有价值补充,将促进 CT 和 MR 增强禁忌或不切实际情况下的腹部横断面成像。

研究设计与样本

  • 综述,描述 UCAs 的物理原理、给药方法、剂量、不良反应及当前与未来的成像技术。

关键影像表现/征象

  • UCAs 由悬浮微泡组成,与超声束强烈相互作用,易被超声成像系统检测。
  • 静脉给药后 UCAs 局限于血池。
  • 高声学振幅可导致微泡碎裂,可能引起毛细血管通透性短期增加或毛细血管破裂。
  • 机械指数 < 0.4 的成像可保留微泡,通常不伴显著生物效应。

临床应用与阅片要点

  • UCAs 基于超过二十年使用的安全性记录,在美国已用于超声心动图,在世界其他地区已用于非心脏成像。
  • 与 CT 和 MR 相比,超声造影具有实时成像、便携性和对金属及运动伪影敏感性降低的优势。
  • UCAs 无肾毒性,可用于肾功能衰竭。
  • 在适当条件下,UCAs 的生物效应可被利用来增强药物递送。
  • 分子靶向超声造影剂通过将微泡外壳与靶向内皮生物标志物的肽、抗体或其他配体结合而制成,这些微泡随后在靶部位微血管中积聚并可被成像。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Microbubble ultrasound contrast agents (UCAs) were recently approved by the Food and Drug administration for non-cardiac imaging. The physical principles of UCAs, methods of administration, dosage, adverse effects, and imaging techniques both current and future are described. UCAs consist of microbubbles in suspension which strongly interact with the ultrasound beam and are readily detectable by ultrasound imaging systems. They are confined to the blood pool when administered intravenously, unlike iodinated and gadolinium contrast agents. UCAs have a proven safety record based on over two decades of use, during which they have been used in echocardiography in the U.S. and for non-cardiac imaging in the rest of the world. Adverse effects are less common with UCAs than CT/MR contrast agents. Compared to CT and MR, contrast-enhanced ultrasound has the advantages of real-time imaging, portability, and reduced susceptibility to metal and motion artifact. UCAs are not nephrotoxic and can be used in renal failure. High acoustic amplitudes can cause microbubbles to fragment in a manner that can result in short-term increases in capillary permeability or capillary rupture. These bioeffects can be beneficial and have been used to enhance drug delivery under appropriate conditions. Imaging with a mechanical index of < 0.4 preserves the microbubbles and is not typically associated with substantial bioeffects. Molecularly targeted ultrasound contrast agents are created by conjugating the microbubble shell with a peptide, antibody, or other ligand designed to target an endothelial biomarker associated with tumor angiogenesis or inflammation. These microbubbles then accumulate in the microvasculature at target sites where they can be imaged. Ultrasound contrast agents are a valuable addition to the diagnostic imaging toolkit. They will facilitate cross-sectional abdominal imaging in situations where contrast-enhanced CT and MR are contraindicated or impractical.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Chong WK, Papadopoulou V, Dayton PA, et al. Imaging with ultrasound contrast agents: current status and future. Abdom Radiol (NY). 2018. PMID: 29508011. doi:10.1007/s00261-018-1516-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。